FDA to hasten review of Immunomedics' pancreatic cancer drug

02/5/2009 | Forbes

Immunomedics' yttrium-90-labeled hPAM4, a treatment for pancreatic cancer, obtained fast-track designation from the FDA. The drug is undergoing early-stage clinical development.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY